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Abstract
Background: Rotator cuff tears can cause significant pain and functional impairment. Without surgical repair, the
rotator cuff has little healing potential, and following surgical repair, they are highly prone to re-rupture. Augmenting
such repairs with a biomaterial scaffold has been suggested as a potential solution. Extracellular matrix (ECM)-based
scaffolds are the most commonly used rotator cuff augments, although to date, reports on their success are variable.
Here, we utilize pre-clinical in vitro and in vivo assays to assess the efficacy of a novel biomaterial scaffold, ovine
forestomach extracellular matrix (OFM), in augmenting rotator cuff repair.
Methods: OFM was assessed in vitro for primary tenocyte growth and adherence, and for immunogenicity using an
assay of primary human dendritic cell activation. In vivo, using a murine model, supraspinatus tendon repairs
were carried out in 34 animals. Augmentation with OFM was compared to sham surgery and unaugmented
control. At 6- and 12-week time points, the repairs were analysed biomechanically for strength of repair and
histologically for quality of healing.
Results: OFM supported tenocyte growth in vitro and did not cause an immunogenic response. Augmentation
with OFM improved the quality of healing of the repaired tendon, with no evidence of excessive inflammatory
response. However, there was no biomechanical advantage of augmentation.
Conclusions: The ideal rotator cuff tendon augment has not yet been identified or clinically implemented. ECM
scaffolds offer a promising solution to a difficult clinical problem. Here, we have shown improved histological
healing with OFM augmentation. Identifying materials that offset the poorer mechanical properties of the rotator
cuff post-injury/repair and enhance organised tendon healing will be paramount to incorporating augmentation
into surgical treatment of the rotator cuff.
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Introduction
Rotator cuff tears are a common cause of significant
shoulder pain and functional impairment and are the most
common cause of shoulder-related disability [1]. They are
estimated to affect 22 % of the general population, and the
prevalence significantly increases with age [2]. Further-
more, with our increasing and ageing population, the
incidence of rotator cuff tears requiring surgical interven-
tion is steadily increasing [3].
Due to the avascular and acellular nature of the rotator
cuff, healing potential is limited without surgical repair
[4–6]. In a rat model of rotator cuff tears, histological ana-
lysis showed that 78 % of tendons had incomplete closure
of the defect site at 12 weeks post defect creation, and
those defects that were fully closed had disorganised tissue
inferior to that of the normal tendon [4]. Even after surgi-
cal repair, healing is suboptimal. In human patients over
the age of 65, only 43 % of patients showed evidence of
healing in a computed tomographic arthrogram or
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magnetic resonance imaging scans 18 months after arthro-
scopic repair of full thickness rotator cuff tears, while 86 %
of patients under 65 years of age showed evidence of heal-
ing [7]. Furthermore, re-tear rates are reported to be as
high as 41 % for double row arthroscopic repairs and 69 %
for single row repairs of large full thickness rotator cuff
tears [8, 9].
Recently, biological augmentation with tissue-engineered
grafts has been suggested as a method for improving heal-
ing outcomes in grades 3 and 4 tears (repairable, full thick-
ness, small to large tears) and as an interposition graft for
grade 5 tears (large retracted tears that are unable to be
apposed) [10]. These grafts can be used either as an onlay
(reinforcement) augmentation, where the graft is placed
over the repaired tendon, or as an intercalary (interposi-
tional) augmentation, where the graft is placed between
the bone and retracted tendon.
Augmentation has two potential benefits: (1) providing
mechanical support and offloading the tendon at the
time of initial repair and (2) improving the rate and/or
quality of healing [11]. Therefore, the ideal graft would
achieve both of these benefits with the added parameters
that it has good suture retention properties and is im-
munologically inert and fully degradable in a biological
setting.
Extracellular matrix (ECM)-based scaffolds are currently
the most commonly used rotator cuff augments [11]. Most
components of ECM are homogenous among different
species allowing properly processed ECM xenografts to be
used with minimal anti-host inflammation [12, 13]. Fur-
thermore, ECM has a complex three-dimensional micro-
structure, involving structural proteins such as collagen,
fibronectin and laminin, glycosaminoglycans (GAGs) and
bioactive growth factors. Combined, these allow for a
degree of mechanical support, but more importantly, pro-
vide host cell attachment sites and a reservoir of growth
factors that encourage cell migration, proliferation and dif-
ferentiation while also modulating angiogenesis and im-
mune response [12].
Recently, clinical confidence in the use of ECM scaffolds
received a significant setback when a porcine non-cross-
linked SIS (Restore™) was associated with hypersensitivity
reactions in 20–30 % of patients [14, 15]. It has been sug-
gested that this reaction was secondary to a large amount
of foreign DNA retained in Restore™ and led to the product
being no longer recommended for use by the American
Academy of Orthopaedic Surgeons [15, 16]. Therefore, all
potential scaffolds need to be thoroughly tested prior to
clinical use and closely monitored following commercial
release.
Decellularized ovine forestomach matrix (OFM) is an
ECM scaffold produced from the lamina propria of the
ovine forestomach. It is decellularized using proprietary
processes that retain the native collagen structure and
secondary molecules that associate with ECM [17]. OFM
is used clinically as a dermal template in the treatment
of chronic wounds [18–20], can act as a template for tis-
sue engineered skin grafts [21] and has also been used
successfully as split thickness skin grafts [22].
Through the studies presented here, we aim to assess
the healing potential of OFM as a novel rotator cuff aug-
mentation graft by thorough in vitro evaluation and as-
sessment in a rat supraspinatus defect model. Clinically,
rotator cuff augmentation could lead to reduced re-tear
rates, earlier mobilisation of the shoulder and thus reduced




The surgical procedure and isolation of primary rat
tenocytes were carried out in accordance with the Insti-
tutional Animal Ethics Committee. Peripheral blood
mononuclear cells were purified from healthy human
volunteer blood and collected according to a protocol
approved by the Institutional Human Participants Ethics
Committee.
Tenocyte cell culture
Primary rat tenocytes were isolated from tendon fascicles of
mature female Wistar rats, as previously described [23].
Briefly, tendon was roughly chopped and digested in dis-
pase and collagenase (both 0.5 mg/mL from Sigma-Aldrich,
USA) in Dulbecco’s modified Eagle’s medium-F12
(DMEM-F12) with 10 % fetal bovine serum (FBS) at
37 °C until all the ECM had been digested. The cell
suspension was passed through a cell strainer, washed
and re-suspended in fresh media. Cells were cultured
in 75 cm2 flasks (Corning Inc., USA) with 10 % FBS/
DMEM-F12 and incubated at 37 °C with 5 % CO2 until
confluent.
Scaffold preparation
OFM was provided by Mesynthes Ltd. (Auckland, New
Zealand) as single-ply, lyophilized biomaterial, terminally
sterilized with ethylene oxide. Samples were pre-
packaged as 1.9-cm diameter discs or grafts pre-cut to
5 × 10 mm.
Qualitative analysis of OFM cytocompatibility
Primary rat tenocytes, isolated as above, were seeded onto
1.9-cm diameter discs of OFM in 24-well plates (Greiner
Bio-One, Germany) for a period of 1, 7 and 14 days in
DMEM-F12 with 5 % FBS at 2.5 × 104 cells/scaffold. At
each time point, scaffolds were stained with calcein AM
(Invitrogen) to visualise live cells, as previously described
[24]. Scaffolds were washed in phosphate-buffered saline
(PBS) and stained for 10 min at 37 °C with 2 μM calcein
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AM in PBS. Scaffolds were washed in fresh PBS and
viewed immediately using fluorescent microscopy; repre-
sentative images were taken to demonstrate cell density
across the scaffold.
Quantitative analysis of OFM cytocompatibility
Primary rat tenocytes, isolated as above, were seeded as
described for the qualitative cytocompatibility assay for a
period of 1, 7 and 14 days. At each time point, viability
was assessed, as previously described [24]. Briefly, 50 μl
alamarBlue® (×100, Invitrogen) (5 % final concentration
in well) was added to each well for 4 h at 37 °C. Follow-
ing this, 200 μl of the alamarBlue® conditioned medium
was transferred to a 96-well plate (Greiner Bio-One) and
fluorescence read using a Synergy 2 multi-detection mi-
croplate reader (BioTek Instruments Inc., USA).
Immunogenicity assay—monocyte-derived dendritic cell
activation
Peripheral blood mononuclear cells were purified from
healthy human volunteer blood. Monocytes were isolated
from peripheral blood mononuclear cells using the Mono-
cyte Isolation Kit II (Miltenyi Biotec, Germany), according
to the manufacturer’s protocol. Immature monocyte-
derived dendritic cells were prepared by culturing the
monocytes for 6 days in RPMI medium supplemented
with 10 % FBS, 100 ng/mL granulocyte macrophage-
colony stimulating factor (GM-CSF) and 50 ng/mL
interleukin-4 (IL-4) (PeproTech, USA).
The immunogenicity of OFM was assessed using imma-
ture dendritic cells, as previously described [24]. Cells
were plated in 24-well plates containing either 5 ng/mL
lipopolysaccharide (LPS; Sigma-Aldrich) or 1.9-cm diam-
eter OFM in RPMI medium with 10 % FBS. The expres-
sion of cell surface markers associated with dendritic cell
maturation was assessed following 40 h of incubation.
Treated dendritic cells were incubated on ice for 20 min
with mouse anti-human antibodies against PE/Cy7-anti-
CD80 (clone 2D10), PerCP/Cy5.5 anti-CD83 (clone HB15e)
and APC anti-CD86 (clone IT2.2) (all supplied by BioLe-
gend, USA). Excess antibody was removed by washing with
PBS containing 1 % FBS. Cell surface markers were ana-
lysed by flow cytometry using the FACS ARIA II (BD Bio-
sciences), and data analysis was performed using FloJo
(version 7.6) (BD Biosciences).
In vivo assessment
Male Sprague-Dawley rats (n = 34), aged greater than
12 weeks and weighing greater than 350 g, underwent sur-
gery. Rats were checked for general health and randomly
distributed into three weight-matched groups: (1) sham
surgery (approach to supraspinatus only), n = 10, (2) unaug-
mented control (single row supraspinatus repair), n = 12
and (3) intervention group (single row repair augmented
with OFM), n = 12.
At least 2 h prior to surgery, rats received a subcuta-
neous injection of the non-steroidal anti-inflammatory
drug (NSAID) Rimadyl (10 μL/g). For anaesthetic induc-
tion, rats were placed in a sealed rodent induction box
with 5 % isoflurane and 2 L O2. Anaesthesia was main-
tained during surgery with 2.5 % isoflurane and 2 L O2
through a specialised nose cone. A 2.5-mL subcutaneous
injection of normal saline was administered immediately
after induction.
The forelimb was prepared by shaving and washing with
2 % chlorhexidine and 70 % ethanol, followed by a sterile
drape (Fig. 1a). An approximately 2-cm-longitudinal inci-
sion was made, centred over the glenohumeral joint,
extending proximally along the belly of supraspinatus and
distally along shaft of humerus (Fig. 1b). The middle belly
of deltoid was incised proximally, in line with muscle
fibres, down to the lateral aspect of the proximal humeral
shaft. The acromio-clavicular joint was incised. The
supraspinatus was easily identified through this approach
(Fig. 1c). A 5-0 prolene stay suture was passed through
the distal supraspinatus. The tendon was incised at its in-
sertion onto the greater tuberosity of the humerus
(Fig. 1d). The insertion site was debrided of any residual
soft tissue (Fig. 1e).
In the unaugmented control group, supraspinatus re-
pair was carried out using the 5-0 prolene stay suture
and a modified Mason-Allen suture technique (Fig. 1f ).
The cut end of the tendon was approximated to the
bony insertion, and the suture ends were tied with a sur-
geon’s knot (Fig. 1g). In the intervention group, the
OFM scaffolds (5 × 10 mm) were rehydrated with sterile
saline, then overlaid longitudinally on the superficial as-
pect of the tendon-bone insertion and incorporated into
the suture repair (passes 2-5) (Fig. 1h).
Following repair, the deltoid and coraco-acromial arch
were lightly approximated with two interrupted 2-0 vicryl
sutures. Skin closure was carried out with a running sub-
cuticular 4-0 monocryl suture with buried knots at either
ends. After closure, 0.4 mL of Marcain (1.25 mg/mL solu-
tion) local anaesthetic was infiltrated around the operation
site.
Rats were closely monitored immediately following sur-
gery. Once sufficiently recovered from the anaesthetic,
they were housed singularly and transferred to a warm-
ing cabinet for one night. Rimadyl (10 μL/g) and 2-mL
normal saline were administered subcutaneously twice
daily for 48 h post-operation. Rats were weighed daily
and checked for signs of illness, pain or distress twice
daily for the first 48 h post-operation. Following this,
they were weighed and checked once daily until 14 days
post-operation. They were then weighed and checked
on a weekly basis.
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At either 6 or 12 weeks post-operatively, rats were hu-
manely sacrificed by CO2 inhalation. The left supraspi-
natus tendon, attached to the whole humerus, was
immediately excised and either placed in formalin for
histological analysis or wrapped in PBS soaked gauze
and stored at −20 °C for later biomechanical analysis.
Biomechanical analysis
Excised shoulders were defrosted in a 37 °C water
bath and kept hydrated with H2O spray throughout
testing. The muscle fibres of the supraspinatus were
removed by gentle scraping, leaving only the distal
tendon attached to the humerus. Suture material was
Fig. 1 Intraoperative guide to in vivo surgery. Micrographs representing each stage of the operative procedure including the preparation and
positioning of the shoulder (a), creating an incision over the humeral head (b), isolating the exposed supraspinatus (c), transecting the
supraspinatus from the humeral head (d), removing residual soft tissue from the humeral head (e), the modified Mason-Allen suture repair (f) and
the unaugmented and augmented supraspinatus tendons (g, h)
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removed to allow testing of the repaired tendon
alone.
Using a specially modified clamp, the humerus and the
tendon were positioned in an Instron machine, with the
tendon at 45° relative to the humerus, to apply load in a
functional position. Specimens underwent a 10-cycle
preconditioning phase (0.1 to 0.5 N at a rate of 1 %/s),
followed by a stress relaxation phase (6 % strain, at a
rate of 5 %/s (0.575 mm/s), followed by 10 min of relax-
ation, then ramp to failure at a rate of 0.3 %/s. Stiffness,
Young’s modulus of elasticity and ultimate load to failure
were then calculated. For each treatment group, at each
time point (6 and 12 weeks) n = 4 samples were tested.
Histological analysis
Excised shoulders were fixed in 10 % neutral buffered for-
malin, processed, decalcified in 10 % formic acid/5 % for-
maldehyde, embedded in paraffin and 5-μm-thick sections
taken. Sections were stained with haematoxylin and eosin
(H&E) and analysed using both transmitted and polarised
light microscopy to evaluate healing. A semi-quantitative
grading system was used based on collagen fibre density,
collagen fibre orientation, quality of healing at bone-
tendon interface, vascularity and presence of inflammatory
cells, as described in Table 1. A total was obtained by
combining the scores for these five parameters, with a
higher score indicating greater healing. Scoring was car-
ried out by a musculoskeletal histopathologist (MD) and
an orthopaedic registrar (MS) who were blinded to treat-
ment details and each other’s scores. A minimum of three
slides per repair were assessed where the tendon-bone
interface could be identified.
Statistical analysis
Data from both the in vitro and in vivo analyses were
analysed using one-way analysis of variance (ANOVA)
with post hoc Tukey’s test using GraphPad Prism Soft-
ware (GraphPad Software, San Diego, CA, USA).
Results
Qualitative and quantitative analysis of OFM
cytocompatibility
Cytocompatibility of OFM was confirmed quantitatively
by alamarBlue™ assay of tenocyte viability and qualita-
tively by calcein AM fluorescent staining of live teno-
cytes. Quantitative analysis demonstrated that tenocyte
cell numbers increase from day 1 to day 7, after which
cell numbers change little up to day 14. Cell growth was
highly variable over the 14-day culture period, as dem-
onstrated by the large error bars. Qualitative analysis
demonstrated that primary rat tenocytes successfully ad-
hered to OFM on day 1 and the number of viable cells
increased over the 14-day period (Fig. 2).
Immunogenicity assay—monocyte-derived dendritic cell
activation
The immunogenicity of implantable scaffolds has been
strongly correlated to the maturation of antigen-presenting
dendritic cells, including the upregulation of dendritic cell
surface proteins such as CD80, CD83 and CD86.
Following 40 h of exposure to OFM, dendritic cell ex-
pression levels of CD80, CD83 and CD86 were unchanged
compared to the low levels expressed by untreated control
dendritic cells (Fig. 3). This was in contrast to dendritic
cells exposed to LPS, which had elevated levels of all three
maturation markers.
In vivo assessment
All surgeries were uneventful with no anaesthetic or op-
erative complications. Post operatively, rats recovered
rapidly, returning to full use of the operated limb within
48–72 h. All 34 animals survived until the experimental
endpoints, and no hypersensitivity reactions were ob-
served. Furthermore, macroscopic inspection of the col-
lected specimens did not reveal any gross infectious or
inflammatory changes.
Biomechanical analysis
An important outcome required when augmenting a ro-
tator cuff repair is for the biomechanical performance of
the tendon to replicate its pre-injury state allowing ap-
propriate forces across the repair to aid healing by im-
proving collagen orientation. In order to assess this, the
repaired rotator cuffs were biomechanically tested along
a functional axis, with stiffness, elasticity and total load
to failure measured. Biomechanical analysis revealed no
significant differences in stiffness, elasticity or load to
failure at either time points.
At 6 weeks post-repair, the stiffness and elasticity of the
augmented rotator cuffs were higher than the unaugmen-
ted controls, although not significant (Fig. 4). Stiffness was
measured at 11.8+/−2.2 N/mm in the augmented group,
Table 1 Histological grading system used to determine the rotator cuff healing outcomes
Collagen fibre density Collagen fibre orientation Bone-tendon interface Vascularity Inflammation
0 None None 0–24 % interdigitation Abundant vascular network Abundant inflammatory cells
1 Low Disorganised fibres 25–49 % interdigitation Moderate vascular network Moderate inflammatory cells
2 Medium Moderate alignment 50–75 % interdigitation Minimal vascular network Minimal inflammatory cells
3 High Highly aligned >75 % interdigitation No vascular network No inflammatory cells
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compared to 9.2+/−2.9 N/mm in the unaugmented group,
and Young’s modulus of elasticity measured at 18.8
+/−5.8 MPa for the augmented group and 8.2+/−2.3 MPa
for the unaugmented group. Similarly, there was no signifi-
cant difference between the unaugmented group and the
sham group, which had a mean stiffness of 10.4+/−4.8 N/
mm and a mean elasticity of 10.5+/−2.9 MPa.
At 12 weeks, there were similarly no differences in the
stiffness and elasticity of all groups. Stiffness was mea-
sured at 11.9+/−1.6 N/mm for the augmented group,
9.1+/−2.2 N/mm for the unaugmented group and 13.9 N/
mm for the sham-operated group. The Young’s modulus of
elasticity measured was measured at 12.7+/−0.82 MPa for
the augmented group, 14.9+/−3.4 MPa for the unaugmen-
ted group and 11.3 MPa for the sham-operated group.
There were no statistically significant differences in the
load to failure of the repaired rotator cuffs. The mean load
to failure was 20+/−2.8 N in the augmented group and
19+/−3.8 N in the unaugmented group at 6 weeks post-
repair, and 23+/−2.4 N and 15+/−2.9 N at 12 weeks post-
repair, respectively. The load to failure of the sham group
was 17+/−3.8 N at 6 weeks and 25+/−6.6 N at 12 weeks.
Histological analysis
At 6 weeks post-op, histological scoring of the repaired ro-
tator cuffs showed no difference between the unaugmen-
ted group and the OFM augmented group, with both
scoring 5.25 out of 15 (Table 2). The sham-operated group
scored significantly higher at 11 out of 15 (Table 2).
Histological analysis at 12 weeks post-op showed the
sham-operated group to have a well-defined tendon-
bone interface, with the collagen fibres of the tendon
appearing dense and well organised (Fig. 5a, b); this was
represented by a histological score of 10.75 (out of 15).
In the unaugmented group, while there was evidence
of the initial stages of an intact tendon-bone interface,
the tendon fibres appeared frayed and disorganised in
nature (Fig. 5c, d), and they therefore scored significantly
lower than the sham group in the histological scoring
(4.25 out of 15).
The rotator cuffs that had been augmented with OFM
had a well-formed tendon-bone interface and a dense col-
lagen fibre network at the tendon; however, the fibres were
largely disorganised and the tenocyte cells present had a
rounded, non-tenocyte-like morphology (Fig. 5e, f ). There
was no significant difference in the histological score of
the OFM group (7 out of 15) compared to either the sham
group or the unaugmented group.
Discussion
Here, we have shown that the novel ovine forestomach
ECM scaffold material is cytocompatible to tenocyte cell
growth, non-immunogenic and improves the histological
appearance of the rotator cuff when used as an overlay
augment in a pre-clinical model of rotator cuff repair.
Tears of the rotator cuff are a common, often painful
and a debilitating problem [1]. Current rotator cuff re-
pairs aim to re-attach the tendon to the humeral head
and debride a partial tear or suture a full thickness tear
Fig. 2 OFM supports primary rat tenocyte growth. Cytocompatibility analysis of primary rat tenocytes cultured on OFM for 1, 7 and 14 days using
alamarBlue™ assay and calcein AM fluorescent staining (a day 1, b day 7, c day 14). Scale bar = 200 μm. Observations were performed three times.
Data presented are representative of these biological repeats. N = 3
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using open or arthroscopic surgeries. While these tech-
niques can be successful, disorganised or incomplete
healing is common [7–9].
Previously, autografts from the biceps tendon or fascia
lata have been trialled as interpositional grafts for improv-
ing rotator cuff repair surgical outcomes [25, 26] as have
allograft rotator cuffs [27]. However, these methods have
had varying results and have not been adopted as com-
mon practice. Biomaterial scaffold augmentation has
therefore been suggested as a means to enhance the heal-
ing outcomes for small to large rotator cuff tears (grade 3
or 4) or when repairing a degenerative tendon [10].
According to a recent study, there were 13 FDA-approved
biomaterial scaffolds available for use in augmenting rota-
tor cuff repair. Of these, nine were ECM-based materials,
three were synthetic and one was an ECM-woven polymer
hybrid [10]. There are limited clinical studies on these
materials, some suggesting that these scaffolds improve
clinical outcomes; however, the results are generally in-
conclusive due to a lack of appropriate controls [28–30].
This leads to the consensus that currently available scaf-
folds, while promising, fail to meet clinical needs [10].
ECM-based scaffolds have been produced from many
sources including dermis, small intestinal submucosa,
pericardium, Achilles tendon and fascia lata of human, bo-
vine, porcine or equine origin [11, 31]. OFM is an ECM
scaffold produced from ovine forestomach. Cellular debris
is removed using a novel decellularisation technique that
maintains more of the natural structure of the ECM and
thus improves the hosts healing response [17]. Previous
studies have shown that OFM is non-toxic, supports
mammalian cell growth and differentiation in vitro and
Fig. 3 OFM does not promote dendritic cell maturation. Representative FACS plots of CD80, CD86 and CD83 expression, as markers of dendritic
cell maturation, following 40 h of culture with OFM and LPS. The shaded area represents the unstained control, the black line is the untreated
control and the red line represents the treatment group as indicated. Three different patient samples were analysed, each experiment run in
duplicates. Data presented are from one patient as representative for the three patients. N = 3
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Fig. 4 The biomechanical profiles of repaired rotator cuffs do not differ post-operatively. Mean stiffness, elasticity and maximal load to failure of
unaugmented and OFM augmented rat shoulders at 6 and 12 weeks post-surgery. Dotted line indicates the mean measurements of sham-operated
shoulders as a reference. N = 4
Table 2 Histological grading of healed rotator cuffs, as scored by a specialist musculoskeletal pathologist and an orthopaedic
registrar based on the criteria set out in Table 1
Group Collagen fibre density Collagen fibre orientation Bone-tendon interface Vascularity Inflammation Total
6 weeks
Sham 2.5 (±0.29) 2.5 (±0.29) 2.5 (±0.29) 2.5 (±0.29) 2.5 (±0.29) 11 (±0.91)
Unaugmented 1.5 (±0.5) 0.75* (±0.48) 1 (±0.71) 1* (±0.41) 1* (±0) 5.25* (±1.60)
OFM augmentation 1.25 (±0.25) 1.25 (±0.25) 1 (±0.65) 0.25* (±0.25) 1* (±0) 5.25* (±0.85)
12 weeks
Sham 2.75 (±0.25) 2.75 (±0.25) 2 (±0.71) 1.25 (±0.48) 2 (±0) 10.75 (±1.44)
Unaugmented 1.5 (±0.5) 0.5* (±0.29) 0.5 (±0.5) 0.5 (±0.29) 1.25 (±0.25) 4.25* (±1.60)
OFM augmentation 2 (±0) 1.25* (±0.25) 2 (±0.41) 0.25 (±0.25) 1.5 (±0.29) 7 (±1)
Data presented are the mean of both scorers ±SEM. One-way ANOVA with post hoc Tukey’s test. N = 2
*p < 0.05 compared to sham
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enhances angiogenesis ex vivo and in vivo [17, 32]. Here,
we have similarly shown that OFM supports the adher-
ence and growth of primary tenocyte cells in vitro, al-
though there did appear to be some variance between
repeat experiments.
OFM has previously been used successfully in clinical
and in vivo studies of wound healing [18–20, 22]; how-
ever, given the history of ECM-based materials in produ-
cing hypersensitivity reactions in patients undergoing
rotator cuff repair [14–16], we feel that prior to pre-
Fig. 5 OFM improves healing of the tendon-bone interface. Representative micrographs of healing at the tendon-bone interface at 12 weeks
post-operatively stained with haematoxylin and eosin and viewed under transmitted light (a, c, e) (left) and polarised light (b, d, f) (right).
a, b Sham-operated shoulders. c, d Unaugmented control shoulders. e, f OFM augmented shoulders. Bone (B), tendon (T), tendon-bone
interface (I). Scale bar represents 400 mm. N = 2
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clinical animal models, it is important to assess the im-
munogenicity of novel biomaterials. Previous studies
have demonstrated that maturation of monocyte-derived
dendritic cells in response to biomaterials is indicative of
in vivo inflammatory responses [33–35]. In this study,
we demonstrated that OFM does not enhance the mat-
uration of primary human dendritic cells in vitro and is
therefore unlikely to illicit an adverse response when im-
planted in vivo.
In order to provide translational evidence that a novel
material is a suitable scaffold, capable of improving the
surgical outcomes of rotator cuff repair, pre-clinical as-
sessment is required in a well-defined animal model of ro-
tator cuff repair. Many animal models have been used to
investigate rotator cuff pathology and repair [36]. Unlike
the rabbit or sheep, the rat has a supraspinatus tendon
enclosed under a bony arch, with a wide range of motion
similar to that of humans, making the rat the recom-
mended model for such procedures [36]. Both extrinsic
and intrinsic insults to the supraspinatus tendon cause
histological and biomechanical deterioration [4, 36],
allowing the model to be used to mimic a wide range of
rotator cuff pathologies and to investigate novel treat-
ments for these pathologies. Here, we found the rat model
to be relatively simple and reproducible, as well as practic-
ally and financially viable.
Augmentation with a biomaterial scaffold aims to both
provide mechanical support to the repair and improve the
quality of tendon healing [11]. In this study, there were no
differences in the biomechanical properties (stiffness, elas-
ticity and load to failure) between the unaugmented or
OFM augmented rotator cuffs. The single-ply lyophilized
OFM, used in this study, has relatively low mechanical
strength compared to the native tendon (load to failure of
15.07 N and suture pull-out of 5.91 N). However, OFM
biomaterial has been fabricated into multi-ply presenta-
tions, with load to failures of over 65 N [37], allowing
scope for a more mechanically robust augment through
tailoring of the fabrication procedure. However, these were
not practical to use in this study due to the relative size of
the rat supraspinatus.
Using overlay augmentation with the OFM scaffold, we
showed improved histological outcomes compared to ani-
mals treated with standard surgical repairs and no signifi-
cant difference in histological scoring between the OFM
augmented tendons and the sham controls. Augmented
tendons had improved collagen fibre density and orienta-
tion, and improved quality of healing at the tendon-bone
interface. Importantly, at neither time points was there
evidence of a hyper-inflammatory response to OFM, as
shown by low vascularity and a low presence of inflamma-
tory cells.
Previous studies have demonstrated that ECM-based ma-
terials induce healing responses by directing macrophage
response down an M2, pro-remodelling phenotype, rather
than the pro-inflammatory M1 phenotype [38]. Given the
improvements in collagen fibre organisation and the lack of
inflammatory responses seen in the histological sections, it
would be of interest to determine what effect OFM has on
macrophage response in tendon repair, although this was
out of the scope of the present study. Similarly, determining
how human tenocytes respond to OFM would be an im-
portant step in future translation from bench to bedside.
Here, rat tenocytes were used as these are directly relevant
to the pre-clinical model being employed.
Conclusion
In conclusion, there is a clear clinical need for improving
surgical outcomes of rotator cuff repair; however, the
ideal biomaterial augment has not been identified or
clinically implemented as yet. Here, we have shown that
OFM as an overlay augment improves the histological
appearance of the rotator cuff post-surgical healing but
does not provide any mechanical benefit in its current
iteration.
Overall, ECM scaffolds offer a promising solution to a
difficult clinical problem. Identifying materials that offset
the poorer mechanical properties of the rotator cuff
post-injury/repair and enhance organised tendon healing
still remain paramount to incorporating augmentation
into current rotator cuff surgical procedures.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors have made contributions to the current work. The manuscript
was written by MS and DSM and critically revised by all authors. The design
of the study was done by DSM, BC, JC and MS. The in vitro cytocompatibility
assessment was carried out by DSM and the immunogenicity assay by JDM
and KB under the supervision of PRD. The surgical procedure and
postoperative care was carried out by MS, DT and KEC. Mechanical testing
was carried out by AT and MS. Histology was carried out by SA and DSM
and analysed by MS and MD. The final data was interpreted by all authors.
All authors read and approved the final manuscript.
Acknowledgements
This study was funded by an Auckland Medical Research Foundation
Postdoctoral Fellowship for D.S. Musson (1 311 002), the Health Research
Council of New Zealand (12/1110), supported by the Medical Technologies
Centre of Research Excellence (MedTech CoRE), funded by the Tertiary
Education Commission of New Zealand and by the European Union Seventh
Framework Programme skelGEN (FP7/2007-2013) under grant agreement
number [318553]. The funders took no part in the analyses or in the writing
of this manuscript.
Author details
1Department of Medicine, The University of Auckland, Private Bag 92019,
Auckland 1142, New Zealand. 2Faculty of Engineering, University of Auckland,
Auckland 1142, New Zealand. 3Waikato District Health Board, Waikato
Hospital, Hamilton 3204, New Zealand. 4Department of Anatomy with
Radiology, The University of Auckland, Auckland 1142, New Zealand. 5School
of Biological Sciences, The University of Auckland, Auckland 1142, New
Zealand. 6Maurice Wilkins Centre, University of Auckland, Private Bag 92014,
Auckland, New Zealand. 7Department of Orthopaedics, Middlemore Hospital,
Private Bag 93311, Auckland, New Zealand.
Street et al. Journal of Orthopaedic Surgery and Research  (2015) 10:165 Page 10 of 11
Received: 6 August 2015 Accepted: 11 October 2015
References
1. Chakravarty K, Webley M. Shoulder joint movement and its relationship to
disability in the elderly. J Rheumatol. 1993;20(8):1359–61.
2. Yamamoto A, Takagishi K, Osawa T, Yanagawa T, Nakajima D, Shitara H,
et al. Prevalence and risk factors of a rotator cuff tear in the general
population. J Shoulder Elbow Surg. 2010;19(1):116–20. doi:10.1016/
j.jse.2009.04.006.
3. Ensor KL, Kwon YW, Dibeneditto MR, Zuckerman JD, Rokito AS. The rising
incidence of rotator cuff repairs. J Shoulder Elbow Surg. 2013;22(12):1628–32.
doi:10.1016/j.jse.2013.01.006.
4. Carpenter JE, Thomopoulos S, Flanagan CL, DeBano CM, Soslowsky LJ.
Rotator cuff defect healing: a biomechanical and histologic analysis in an
animal model. J Shoulder Elbow Surg. 1998;7(6):599–605.
5. Kartus J, Kartus C, Rostgard-Christensen L, Sernert N, Read J, Perko M. Long-
term clinical and ultrasound evaluation after arthroscopic acromioplasty in
patients with partial rotator cuff tears. Arthroscopy. 2006;22(1):44–9.
doi:10.1016/j.arthro.2005.07.027.
6. Massoud SN, Levy O, Copeland SA. Subacromial decompression. Treatment
for small- and medium-sized tears of the rotator cuff. J Bone Joint Surg.
2002;84(7):955–60.
7. Boileau P, Brassart N, Watkinson DJ, Carles M, Hatzidakis AM, Krishnan SG.
Arthroscopic repair of full-thickness tears of the supraspinatus: does the
tendon really heal? J Bone Joint Surg Am. 2005;87(6):1229–40. doi:10.2106/
JBJS.D.02035.
8. DeHaan AM, Axelrad TW, Kaye E, Silvestri L, Puskas B, Foster TE. Does
double-row rotator cuff repair improve functional outcome of patients
compared with single-row technique? A systematic review. Am J Sport
Med. 2012;40(5):1176–85.
9. Duquin TR, Buyea C, Bisson LJ. Which method of rotator cuff repair leads to
the highest rate of structural healing? A systematic review. Am J Sports
Med. 2010;38(4):835–41. doi:10.1177/0363546509359679.
10. Derwin KA, Badylak SF, Steinmann SP, Iannotti JP. Extracellular matrix
scaffold devices for rotator cuff repair. J Shoulder Elbow Surg.
2010;19(3):467–76. doi:10.1016/j.jse.2009.10.020.
11. Ricchetti ET, Aurora A, Iannotti JP, Derwin KA. Scaffold devices for rotator
cuff repair. J Shoulder Elbow Surg. 2012;21(2):251–65. doi:10.1016/
j.jse.2011.10.003.
12. Badylak S, Obermiller J, Geddes L, Matheny R. Extracellular matrix for
myocardial repair. Heart Surg Forum. 2003;6(2):E20–6.
13. van der Rest M, Garrone R. Collagen family of proteins. FASEB J.
1991;5(13):2814–23.
14. Iannotti JP, Codsi MJ, Kwon YW, Derwin K, Ciccone J, Brems JJ. Porcine
small intestine submucosa augmentation of surgical repair of chronic
two-tendon rotator cuff tears. A randomized, controlled trial. J Bone Joint
Surg Am. 2006;88(6):1238–44. doi:10.2106/JBJS.E.00524.
15. Walton JR, Bowman NK, Khatib Y, Linklater J, Murrell GAC. Restore
orthobiologic implant: not recommended for augmentation of rotator cuff
repairs. J Bone Joint Surg-Am Vol. 2007;89A(4):786–91.
16. Zheng MH, Chen J, Kirilak Y, Willers C, Xu J, Wood D. Porcine small intestine
submucosa (SIS) is not an acellular collagenous matrix and contains porcine
DNA: possible implications in human implantation. J Biomed Mater Res B
Appl Biomater. 2005;73(1):61–7. doi:10.1002/jbm.b.30170.
17. Lun S, Irvine SM, Johnson KD, Fisher NJ, Floden EW, Negron L, et al. A
functional extracellular matrix biomaterial derived from ovine forestomach.
Biomaterials. 2010;31(16):4517–29. doi:10.1016/j.biomaterials.2010.02.025.
18. Bohn GA, Gass K. Leg ulcer treatment outcomes with new ovine collagen
extracellular matrix dressing: a retrospective case series. Adv Skin Wound
Care. 2014;27(10):448–54. doi:10.1097/01.ASW.0000453728.12032.6f.
19. Liden BA, May BC. Clinical outcomes following the use of ovine
forestomach matrix (endoform dermal template) to treat chronic wounds.
Adv Skin Wound Care. 2013;26(4):164–7. doi:10.1097/
01.ASW.0000428862.34294.d4.
20. Simcock JW, Than M, Ward BR, May BC. Treatment of ulcerated necrobiosis
lipoidica with ovine forestomach matrix. J Wound Care. 2013;22(7):383–4.
doi:10.12968/jowc.2013.22.7.383.
21. Merrilees MJ, Falk BA, Zuo N, Dickinson ME, May BC, Wight TN. Use of
versican variant V3 and versican antisense expression to engineer cultured
human skin containing increased content of insoluble elastin. J Tissue Eng
Regen Med. 2014. doi:10.1002/term.1913.
22. Simcock J, May BC. Ovine forestomach matrix as a substrate for single-stage
split-thickness graft reconstruction. Eplasty. 2013;13:e58.
23. Chhana A, Callon KE, Dray M, Pool B, Naot D, Gamble GD, et al. Interactions
between tenocytes and monosodium urate monohydrate crystals:
implications for tendon involvement in gout. Ann Rheum Dis.
2014;73(9):1737–41. doi:10.1136/annrheumdis-2013-204657.
24. Musson DS, Naot D, Chhana A, Matthews BG, McIntosh JD, Lin ST, et al. In vitro
evaluation of a novel non-mulberry silk scaffold for use in tendon regeneration.
Tissue Eng Part A. 2015;21(9-10):1539–51. doi:10.1089/ten.TEA.2014.0128.
25. Ito J, Morioka T. Surgical treatment for large and massive tears of the rotator
cuff. Int Orthop. 2003;27(4):228–31. doi:10.1007/s00264-003-0459-4.
26. Neviaser JS. Ruptures of the rotator cuff of the shoulder. New concepts in
the diagnosis and operative treatment of chronic ruptures. Arch Surg.
1971;102(5):483–5.
27. Moore DR, Cain EL, Schwartz ML, Clancy Jr WG. Allograft reconstruction for
massive, irreparable rotator cuff tears. Am J Sports Med. 2006;34(3):392–6.
doi:10.1177/0363546505281237.
28. Barber FA, Burns JP, Deutsch A, Labbe MR, Litchfield RB. A prospective,
randomized evaluation of acellular human dermal matrix augmentation for
arthroscopic rotator cuff repair. Arthroscopy. 2012;28(1):8–15. doi:10.1016/
j.arthro.2011.06.038.
29. Burkhead WZ, Schiffern SC, Krishnan SG. Use of graft jacket as an
augmentation for massive rotator cuff tears. Semin Arthroplasty.
2007;18(1):11–8. doi:10.1053/j.sart.2006.11.017.
30. Wong I, Burns J, Snyder S. Arthroscopic graft jacket repair of rotator cuff tears.
J Shoulder Elbow Surg. 2010;19(2 Suppl):104–9. doi:10.1016/j.jse.2009.12.017.
31. Badylak SF. The extracellular matrix as a biologic scaffold material.
Biomaterials. 2007;28(25):3587–93. doi:10.1016/j.biomaterials.2007.04.043.
32. Irvine SM, Cayzer J, Todd EM, Lun S, Floden EW, Negron L, et al.
Quantification of in vitro and in vivo angiogenesis stimulated by ovine
forestomach matrix biomaterial. Biomaterials. 2011;32(27):6351–61.
doi:10.1016/j.biomaterials.2011.05.040.
33. Foti M, Granucci F, Pelizzola M, Beretta O, Ricciardi-Castagnoli P. Dendritic cells
in pathogen recognition and induction of immune responses: a functional
genomics approach. J Leukoc Biol. 2006;79(5):913–6. doi:10.1189/jlb.1005547.
34. Norton LW, Park J, Babensee JE. Biomaterial adjuvant effect is attenuated by
anti-inflammatory drug delivery or material selection. J Control Release.
2010;146(3):341–8. doi:10.1016/j.jconrel.2010.05.032.
35. Kou PM, Pallassana N, Bowden R, Cunningham B, Joy A, Kohn J, et al.
Predicting biomaterial property-dendritic cell phenotype relationships from
the multivariate analysis of responses to polymethacrylates. Biomaterials.
2012;33(6):1699–713. doi:10.1016/j.biomaterials.2011.10.066.
36. Soslowsky LJ, Carpenter JE, DeBano CM, Banerji I, Moalli MR. Development
and use of an animal model for investigations on rotator cuff disease.
J Shoulder Elbow Surg. 1996;5(5):383–92.
37. Floden EW, Malak SF, Basil-Jones MM, Negron L, Fisher JN, Lun S, et al.
Biophysical characterization of ovine forestomach extracellular matrix
biomaterials. J Biomed Mater Res B Appl Biomater. 2011;96(1):67–75.
doi:10.1002/jbm.b.31740.
38. Badylak SF, Valentin JE, Ravindra AK, McCabe GP, Stewart-Akers AM.
Macrophage phenotype as a determinant of biologic scaffold remodeling.
Tissue Eng Part A. 2008;14(11):1835–42. doi:10.1089/ten.tea.2007.0264.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Street et al. Journal of Orthopaedic Surgery and Research  (2015) 10:165 Page 11 of 11
